Remdesivir is an antiviral approved for COVID-19 treatment, but its wider use is limited by
intravenous delivery. An orally bioavailable remdesivir analog may boost therapeutic benefit
by facilitating early administration to non-hospitalized patients. This study characterizes the
anti-SARS-CoV-2 efficacy of GS-621763, an oral prodrug of remdesivir parent nucleoside
GS-441524. Both GS-621763 and GS-441524 inhibit SARS-CoV-2, including variants of
concern (VOC) in cell culture and human airway epithelium organoids. Oral GS-621763 is …

Remdesivir is the only small-molecule antiviral approved to date for COVID-19 treatment, but
its wider use is limited by intravenous delivery. An orally bioavailable remdesivir analog may
boost therapeutic benefit by facilitating early administration to non-hospitalized patients. This
study characterized the anti-SARS-CoV-2 efficacy of GS-621763, an oral prodrug of
remdesivir parent nucleoside GS-441524. Both GS-621763 and GS-441524 inhibited SARS-
CoV-2, including variants of concern (VoC) in cell culture. Oral GS-621763 was efficiently …